These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 16192623)

  • 1. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandala M; Papaldo P; Nistico C; Fabi A; Cuppone F; Gelibter A; Terzoli E; Cognetti F
    J Clin Oncol; 2005 Oct; 23(28):7248-50; author reply 7250. PubMed ID: 16192623
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
    Hull RD; Pineo GF; Stein P
    Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients.
    Levine M
    Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():9-11. PubMed ID: 14730472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?
    Caine GJ; Lip GY
    Arch Intern Med; 2003 May; 163(10):1243-4; author reply 1244. PubMed ID: 12767973
    [No Abstract]   [Full Text] [Related]  

  • 5. The optimal long-term treatment of venous thromboembolism.
    Prandoni P
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):729-32. PubMed ID: 16170889
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low molecular weight heparin--a safer anticoagulant in thrombosis and cancer].
    Schulman S
    Lakartidningen; 2004 May; 101(19):1712-5. PubMed ID: 15188585
    [No Abstract]   [Full Text] [Related]  

  • 8. Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandalà M; Ciccarese M; Papaldo P; Fabi A; Cognetti F
    Thromb Res; 2007; 119(4):525-9. PubMed ID: 16780933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of venous thromboembolism among hospitalized medical patients.
    Goldhaber SZ; Turpie AG
    Circulation; 2005 Jan; 111(1):e1-3. PubMed ID: 15630031
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of venous thromboembolism in cancer patients.
    Levine MN; Lee AY
    Semin Thromb Hemost; 1999; 25(2):245-9. PubMed ID: 10357092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis.
    Cunningham RS
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S17-25; quiz S41-2. PubMed ID: 16638457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin and CXCL12 dimerization.
    Altundag K; Altundag O; Atik MA
    J Clin Oncol; 2005 Oct; 23(28):7248. PubMed ID: 16192624
    [No Abstract]   [Full Text] [Related]  

  • 13. [Heparin and cancer].
    Lykke J
    Ugeskr Laeger; 2006 Dec; 168(50):4397-401. PubMed ID: 17217864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant treatment of deep vein thrombosis and pulmonary embolism.
    Tran H; McRae S; Ginsberg J
    Cardiol Clin; 2008 May; 26(2):235-50, vi-vii. PubMed ID: 18406997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Wille-Jorgensen P
    Br J Surg; 2006 Mar; 93(3):374; author reply 375-6. PubMed ID: 16498577
    [No Abstract]   [Full Text] [Related]  

  • 16. Venous thromboembolism and cancer: prevention and therapy.
    Lee AY
    Vnitr Lek; 2006 Mar; 52 Suppl 1():127-8, 130-1. PubMed ID: 16637461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparins for the long-term treatment of cancer patients with venous thromboembolism.
    Prandoni P
    J Support Oncol; 2006 Mar; 4(3):127-8. PubMed ID: 16553138
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Agnelli G; Bergqvist D; Dahl O; Eriksson B; Rud Lassen M; Mouret P; Rosencher N
    Br J Surg; 2006 Mar; 93(3):375; author reply 375-6. PubMed ID: 16498579
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Tangelder MJ; Bylock A; Held P
    Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.